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Abnormal joint powers before and after the onset
of claudication symptoms
Panagiotis Koutakis, BS,a Jason M. Johanning, MD,b Gleb R. Haynatzki, PhD,c Sara A. Myers, MS,a
Nicholas Stergiou, PhD,a G. Matthew Longo, MD,b and Iraklis I. Pipinos, MD,b Omaha, Neb
Objective: Claudication is the most common manifestation of peripheral arterial disease, producing significant ambulatory
compromise. Our study evaluated patients with bilateral lower limb claudication and characterized their gait abnormality
based on advanced biomechanical analysis using joint torques and powers.
Methods: Twenty patients with bilateral claudication (10 with isolated aortoiliac disease and 10 with combined aortoiliac
and femoropopliteal disease) and 16 matched controls ambulated on a walkway while 3-dimensional biomechanical data
were collected. Patients walked before and after onset of claudication pain. Joint torques and powers at early, mid, and
late stance for the hip, knee, and ankle joints were calculated for claudicating patients before and after the onset of
claudication pain and were compared to controls.
Results: Claudicating patients exhibited significantly reduced hip and knee power at early stance (weight-acceptance
phase) due to decreased torques produced by the hip and knee extensors. In mid stance (single-limb support phase),
patients had significantly reduced knee and hip power due to the decreased torques produced by the knee extensors and
the hip flexors. In late stance (propulsion phase), reduced propulsion was noted with significant reduction in ankle plantar
flexor torques and power. These differences were present before and after the onset of pain, with certain parameters
worsening in association with pain.
Conclusions: The gait of claudication is characterized by failure of specific and identifiable muscle groups needed to
perform normal walking (weight acceptance, single-limb support, and propulsion). Parameters of gait are abnormal with
the first steps taken, in the absence of pain, and certain of these parameters worsen after the onset of claudication pain.
( J Vasc Surg 2010;52:340-7.)

Intermittent claudication is the most common clinical
manifestation of peripheral arterial disease (PAD), presenting
as exercise-induced leg muscle pain and gait dysfunction.1
Claudication and its associated ambulatory impairment produce impaired quality of life,2 physical dependence,3 and poor
health outcomes.4 Previous work suggests that PAD patients
walk slower, with decreased cadence, increased stance time,
shorter stride length, and a narrower step width than healthy
controls.5,6 However, these changes alone are unable to describe in sufficient detail the locomotor impairments of claudicating patients or aid in our understanding of its underlying
pathophysiology.
A more detailed quantitative evaluation of gait can be
obtained using advanced biomechanical analysis that includes joint torques and powers.7,8 Although muscles proFrom the Nebraska Biomechanics Core Facility, University of Nebraska at
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duce linear forces, motions at joints are all rotary. The
rotary torque is a measure of the tendency of a force to
rotate the limb around a joint and is calculated as the
product of the muscle force and the distance from the joint
center that the force is being applied. The net muscle
torque does not represent any one particular muscle but
rather describes the net activity of all the muscles acting
across a joint.
Joint power can be defined as the rate of work produced
by muscles contracting to move a joint and is determined as
the product of the net torque (moment) of the muscles acting
across a joint and the resulting angular velocity of the joint.
Joint powers have been used extensively to identify the mechanisms responsible for pathologic gait in populations such as
elderly patients and those with knee and hip arthritis and
arthroplasty and anterior cruciate ligament reconstruction.8-10 Joint powers can also assess and guide successful rehabilitation strategies.10 Similar insights can be
gained from patients with PAD by using this approach.
Previous studies of claudicating PAD patients from our
laboratory using basic biomechanical analysis7,11-13 suggested a potential weakness of the posterior compartment
muscles of the hip and calf as key components of PAD gait
impairment. The purpose of the current study was to use
joint torques and powers to isolate and identify the individual muscle compartments responsible for the gait impairment of claudicating patients.
METHODS
This study was approved by the Institutional Review
Boards of the Western Iowa and the University of Nebraska
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Fig 1. An illustration of the three phases of walking with the dominant flexor and extensor muscle groups that are
involved in each phase based on the joint torques generated. The dominant muscle groups are identified in black if they
contract concentrically (muscle shortens as it contracts) and in grey if they contract eccentrically (muscle lengthens as
it contracts). A, Weight-acceptance phase, also known as early stance, initial contact, and heel-strike phase, lasts from
ipsilateral heel strike to contralateral toe-off, thus covering the first double-support phase (initial 20% of stance). The
right leg is accepting most of the weight of the body as it descends from previously being in single support on the left
leg. The right hip extensors concentrically contract to extend the hip (reflected in the HET torque and H1 power in
Tables III and IV), the knee extensors eccentrically contract to allow the knee to bend (reflected in the KET torque and
K1 power in Tables III and IV), and the ankle dorsi flexors eccentrically contract to maintain ankle dorsi flexion
(reflected in the ADT torque and A1 power in Tables III and IV). B, Single-limb support phase, also known as the
mid-stance phase, lasts from contralateral (here left) toe-off until contralateral heel strike. During single support, the
center of mass of the body is at its highest point and over the extended ipsilateral (here right) leg. The body has
maximum potential energy getting ready to fall forward for the next double support. Limited muscular contractions are
needed during this phase except its early part where the knee extensors contract concentrically to extend the knee and
straighten the leg (reflected in the KET torque and K2 power in Tables III and IV) and the late part where the hip
flexors contract eccentrically to control the movement of the pelvis (reflected in the HFT torque and H2 power in
Tables III and IV). C, Propulsion phase, or the late stance or toe-off phase, lasts from contralateral heel strike to
ipsilateral toe-off. It is the last 20% of stance and the second-double support phase. The body is propelled forward onto
the extended left leg mainly by the action of the right ankle plantar flexors (posterior calf compartment muscles, the
most important of which are the gastrocnemius and soleus). Functionally, these muscles contract concentrically
(reflected in the APT torque and A3 power in Tables III and IV) and accelerate the trunk forward and upward over the
left leg (ie, providing forward progression and weight support). In this phase, the knee flexors eccentrically contract,
controlling the knee movement (reflected in the KFT torque and K3 power in Tables III and IV) and the hip flexors
concentrically contract (reflected in the HFT torque and H3 power in Tables III and IV) to assist the ankle plantar
flexors to accelerate the trunk forward and lift the leg over the ground into the swing phase.

Medical Centers. All individuals signed an inform consent
before they participated in the study.
Key events during gait stance. The gait cycle (from
heel touchdown to heel touchdown) consists of a stance
and a swing period. The stance phase is the most important
segment of the gait cycle because the ambulating limb
accepts, supports, and propels forward the weight of
the body and is the only portion of the gait cycle that can be
accurately evaluated for joint moments and powers. The
stance segment can be divided in three distinct phases: the
weight-acceptance, the single-limb support, and the propulsion phases (Fig 1).
Participant inclusion and exclusion criteria. The
study recruited 20 patients diagnosed with moderate arterial occlusive disease and bilateral claudication (Fontaine
stage II and Rutherford grade 1 categories 2 and 3)14 from
the vascular surgery clinics of the VA Nebraska and Western
Iowa and University of Nebraska Medical Centers. All 20
PAD patients had aortoiliac occlusive disease (10 with

isolated aortoiliac disease and 10 with femoropopliteal
disease.) The diagnosis of the level of disease was made with
the use of computed tomography angiography and ultrasound evaluation.
In addition, 16 healthy controls were recruited,
matched for gender, age, body mass, and height. The
controls were matched to PAD patients by group/frequency matching. Patients and controls were screened and
evaluated by two board-certified vascular surgeons.
The study excluded PAD patients with ambulationlimiting cardiac, pulmonary, neuromuscular, or musculoskeletal disease, or those who experienced pain or discomfort during walking for any reason other than claudication
(ie, arthritis, low back pain, musculoskeletal problems, and
neuropathy). Patient evaluation included resting anklebrachial index (ABI; a measurement ⬍0.90 was present in
all claudicant patients), detailed history, physical examination, and direct assessment and observation of the patient’s
walking impairment. A vascular surgeon observed the pa-
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tient walking and recorded all symptoms and signs affecting
ambulation to ensure limitation was secondary to claudication pain.
Controls had a resting ABI ⬎0.90 and no subjective or
objective ambulatory dysfunction. Controls were screened
in a similar fashion as PAD patients and were excluded for
the same ambulation-limiting problems or if pain was experienced during walking. The gait of all recruited participants was tested in the Biomechanics Laboratory of the
University of Nebraska at Omaha.
Experimental procedure and data collection. Before
data collection, reflective markers were placed at specific
anatomic locations of each participant’s lower limb using
the modified Helen Hayes marker set.12 Each participant
was directed to walk with a self-selected pace over a 10meter pathway, while 3-dimensional marker trajectories
(kinematics) and ground reaction forces (kinetics) were
simultaneously collected. The marker trajectories were captured with an eight high-speed real-time camera system
(EvaRT 5.0, Motion Analysis Corp, Santa Rosa, Calif)
sampling at 60 Hz. The ground reaction force data were
acquired with a Kistler force platform sampling at 600 Hz.
Each patient was tested before (“pain-free” condition)
and after (“pain” condition) the onset of claudication pain.
During pain-free testing, mandatory rest occurred between
the walking trials to ensure that all trials were in a pain-free
condition. Once patients completed all pain-free trials, the
pain trials were performed. Each patient was asked to walk
on an inclined treadmill with 10% grade at a speed of 0.67
m/s15 until claudication pain was established. The patients
were then immediately returned to the collection walkway
to acquire the data for the pain condition without the
mandatory resting periods. Controls completed only the
pain-free condition trials. Five walking trials were collected
from each leg of the participants for each condition.
Data analysis. Joint kinetics and kinematics were
calculated for the sagittal plane during the stance phase
of walking. An inverse dynamic solution was performed
to calculate joint muscle torques and powers from the
joint kinetics and kinematics.8 Joint muscle power (Pj) is
calculated as the product of the net torque of force at a joint
(Tj) and the relative joint angular velocity (j) or Pj ⫽ Tj ⫻
j (Joules/s or Watts). Power combines kinetic (forces)
and kinematic (angles and velocities) information and can
be expressed positively or negatively. Positive power indicates that energy is being generated and negative power
that energy is being absorbed by the muscle group under
study. Thus, positive joint muscle power is associated with
concentric muscular contractions, and negative power is
associated with eccentric muscular contractions.8
Joint torques and joint muscle powers were normalized
with respect to the participant’s body mass and expressed as
a percentage of the stance phase. The peak values for
extensor and flexor torques were identified for the ankle,
knee, and hip joints.8 The variables identified were the
ankle dorsi flexor torque (ADT) in early stance and
the ankle plantar flexor torque (APT) in late stance for
the ankle, the knee extensor torque (KET) in early stance

and the knee flexor torque (KFT) in late stance for the knee,
and the hip extensor torque (HET) in early stance and the
hip flexor torque (HFT) in late stance for the hip.
The peak values for power absorption (eccentric contraction) and generation (concentric contraction) were
identified for the ankle, knee, and hip joints.8 The power
variables identified were the power absorption in early (A1)
and mid (A2) stance and the power generation in late
stance (A3) for the ankle; the power absorption in early
stance (K1), the power generation in the early part of
mid-stance (K2), and the knee power absorption in late
stance (K3) for the knee, and the power generation in early
stance (H1), the power absorption in mid stance (H2), and
the power generation in late stance (H3) for the hip joint.8
Custom-made Matlab (Matlab 2008b, Mathworks Inc,
Concord, Mass) software was used to calculate the joint
torques and powers.
Statistical analysis. Data were summarized by group
means and standard deviations of the peak joint torques and
powers. These were calculated for each testing condition
for controls and for pain-free and pain conditions for claudicating patients by first averaging the limb measurements
for each individual and then averaging the obtained averages overall for the 20 patients in the claudicating group
and, respectively, for 16 controls.
When the effects of predictors on response variables
were modeled, repeated measures models were developed
where the unit of analysis was the limb (not participant),
and the individual’s two limbs were “nested” in him or her
to account for possible correlation between the two
limbs in a person. Three separate comparisons were
performed: (1) Controls vs claudicating patients in painfree condition; (2) controls vs claudicating patients in
pain condition; and (3) claudicating patients in pain-free
condition vs claudicating patients in pain condition. For
comparisons 1 and 2, linear models with repeated measures on variable leg (left vs right) were used; whereas for
comparison 3, linear models with doubly repeated measures on variables leg (left vs right) and pain status
(before pain vs after pain) were used.
In addition to the main effects of group and leg for 1
and 2, or pain status and leg for 3, first-order interaction
terms were also included in the models. Additionally, in all
models we controlled for variable ABI and, particularly for
comparison 3, we also controlled for variable level of disease (aortoiliac only vs aortoiliac plus femoropopliteal).
The concrete values for P were always reported. The
level of significance was set to 0.05. The procedure MIXED
in the SAS 9.2 software (SAS Institute, Cary, NC) was used
to develop all linear models.
RESULTS
Temporal and spatial gait measurements. The baseline clinical characteristics of patients and healthy controls
are reported in Table I. No significant differences were
found between groups for age, body mass, and height.
When compared with controls, PAD patients had significantly decreased gait velocity, stride length, and step
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Table I. Baseline characteristics of peripheral arterial
disease patients and healthy controls
Clinical characteristics
Gender
Male
Female
Age, mean ⫾ SD, y
Body mass, mean ⫾ SD, kg
Body height, mean ⫾ SD, m
Disease duration,
mean ⫾ SD, y
ABI, mean ⫾ SD
Right limb
Left limb
Smokers, No. (%)
Hypertension, No. (%)
Diabetes mellitus, No. (%)
Hyperlipidemia, No. (%)
BMI, mean ⫾ SD, kg/m2

PAD
(n ⫽ 20)

Control
(n ⫽ 16)

19
1
60.25 ⫾ 7.21
82.55 ⫾ 18.05
1.73 ⫾ 0.07

15
1
62.81 ⫾ 12.01
81.79 ⫾ 20.99
1.73 ⫾ 0.08

4.01 ⫾ 2.18
⬍0.9
0.58 ⫾ 0.22
0.57 ⫾ 0.18
15 (75)
14 (70)
1 (5)
15 (75)
27.72 ⫾ 5.35

0
⬎0.9
1.11 ⫾ 0.05
1.10 ⫾ 0.04
0 (0)
2 (12.5)
0 (0)
2 (12.5)
27.11 ⫾ 5.32

ABI, Ankle-brachial index; BMI, body mass index; PAD, peripheral arterial
disease; SD, standard deviation.

length, and increased step width (Table II). The differences
for these parameters remained significant when the patients
walked, experiencing muscle pain in the pain condition
(Table II). A comparison of temporal and spatial gait
measurements before and after onset of claudication
showed a significant decrease in gait velocity (Table II).
Weight-acceptance phase. Compared with the controls, patients in the pain-free condition generated significantly decreased torque by the hip extensors (HET)
and by the knee extensors (KET), which translated to
significantly decreased power at the hip (H1, reduced
concentric contraction of the hip extensors) and at the
knee (K1, reduced eccentric contraction of the knee
extensors; Tables III and IV). Decreased (although not
significant) power absorption was produced at the ankle
(A1, reduced eccentric contraction of the ankle dorsi
flexors). In the pain condition, the results for the knee
extensor torque (KET), the concentric contraction of the
hip extensors (H1), and the eccentric contraction of the
ankle dorsi flexors (A1) remained significantly different
compared with controls (Table III).
Single-limb support or mid-stance phase (all the
body weight on one limb). Compared with the controls,
patients in pain-free and pain conditions generated significantly decreased torque by the knee extensors (KET) and
the hip flexors (HFT), which then translated to significantly
decreased knee joint power generation in the early part of
the mid-stance phase (K2, reduced concentric contraction
of the knee extensors) and decreased hip power absorption
in the late part of mid-stance (H2, reduced eccentric contraction of the hip flexors; Tables III, IV).
Propulsion or late-stance phase. Compared with the
controls, patients in pain-free and pain conditions generated significantly decreased torque by the ankle plantar
flexors (APT) and the hip flexors (HFT), which translated

to significantly less power at the ankle (A3, reduced concentric contraction of the ankle plantar flexors) and the hip
(H3, reduced concentric contraction of the hip flexors in
the pain condition; Tables III, IV). Patients in both conditions also absorbed significantly less power at the level of
the knee flexors (K3, reduced eccentric contraction of the
knee flexors). Once in the pain condition, patients generated significantly decreased ankle plantar flexor torque
(APT) than in the pain-free condition. This significant
decrease in torque (reduced concentric contraction of the
ankle plantar flexors) translated into further decrease of
power generation at the ankle (A3).
DISCUSSION
The purpose of this study was to use joint torques and
powers to characterize and provide an in depth understanding of the gait impairment of claudicating patients. Joint
torques and powers were measured while patients walked,
with and without claudication pain, and were compared
with those of healthy controls matched for gender, height,
body mass, and age. Our results from the temporal and
spatial gait parameters demonstrate that the character of
the PAD gait is overall “sluggish and tired.” Patients with
claudication have decreased gait velocity, decreased stride,
and step length, and increased step width. These findings
are in agreement with previous studies and unequivocally
document the abnormal temporal and spatial gait parameters of claudicating PAD patients.5,6
By using advanced biomechanical analysis in the form
of joint torques and powers, we were able to isolate and
describe the specific muscle group impairments that operate to produce the gait deficit in claudicating patients. Our
data demonstrate a decreased ability of the knee and hip
extensors to control weight acceptance and of the ankle
dorsi flexors to eccentrically control the lowering of the
foot to the ground after heel strike in early stance. In mid
stance we found a decreased ability of the knee extensors to
concentrically extend the knee and of the hip flexors to
eccentrically control the movement of the pelvis. Finally, in
late stance we demonstrated a decreased ability of the ankle
plantar flexors and of the hip flexors to concentrically
propel the body forward and of the knee flexors to eccentrically control knee hyperextension as the trunk is accelerated forward.
Decreased weight acceptance. Trunk support in early
stance is provided by the hip extensors concentrically contracting to extend the hip (H1), the knee extensors eccentrically contracting to allow the knee to flex (K1), and the
ankle dorsi flexors, which eccentrically control the movement of the foot towards full contact with the ground
(A1).16 Our findings in PAD patients demonstrate that all
three muscle groups involved in the weight-acceptance
phase produce less power than in controls. Specifically PAD
patients have decreased power generation by the hip extensors (gluteus muscles, H1) and the knee extensors (quadriceps) in early stance (K1), indicating decreased ability to
support the body weight. These power results are sup-
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Table II. Group means and standard deviations for the temporal and spatial gait measurements for peripheral arterial
disease (PAD) and control groups

Measurement
Gait velocity, m/s
Stride length, m
Cadence, steps/min
Step length, m
Step width, m
Stance phase, % of gait cycle
Swing phase, % of gait cycle
Double support, % of gait cycle

PAD (N ⫽ 20)

Control
(N ⫽ 16)

PAD-PF

P

1.28 ⫾ 0.13
1.47 ⫾ 0.11
106.41 ⫾ 7.45
0.68 ⫾ 0.05
0.13 ⫾ 0.03
62.25 ⫾ 4.45
37.75 ⫾ 2.11
12.60 ⫾ 2.91

1.14 ⫾ 0.10
1.30 ⫾ 0.13
101.03 ⫾ 8.44
0.64 ⫾ 0.06
0.15 ⫾ 0.03
61.80 ⫾ 4.26
38.20 ⫾ 3.70
12.93 ⫾ 1.76

.0051
⬍.001
.053
.013
.045
.356
.678
.453

a

PAD-P

Pb

Pc

1.09 ⫾ 0.13
1.27 ⫾ 0.11
101.58 ⫾ 7.82
0.61 ⫾ 0.05
0.15 ⫾ 0.04
63.20 ⫾ 4.10
36.80 ⫾ 3.33
13.04 ⫾ 2.23

.0007
⬍.001
.051
.011
.050
.367
.308
.274

.042
.526
.256
.132
.385
.236
.448
.499

PAD-P, Pain condition; PAD-PF, pain-free condition.
a
Differences between PAD-PF and control (P ⬍ .05 is significant).
b
Differences between PAD-P and control (P ⬍ .05 is significant).
c
Differences between PAD-PF and PAD-P (P ⬍ .05 is significant).

Table III. Group means and standard deviations (N ⫻ m/kg) for joint torques of the ankle, knee, and hip joint for
peripheral arterial disease (PAD) and control groups

Variable
ADT
APT
KET
KFT
HET
HFT

PAD (N ⫽ 20)

Control
(N ⫽ 16)

PAD-PF

P

PAD-P

Pb

Pc

⫺0.361 ⫾ 0.101
1.356 ⫾ 0.138
0.746 ⫾ 0.186
⫺0.137 ⫾ 0.128
0.901 ⫾ 0.248
⫺1.061 ⫾ 0.231

⫺0.332 ⫾ 0.103
1.289 ⫾ 0.129
0.514 ⫾ 0.291
⫺0.197 ⫾ 0.241
0.756 ⫾ 0.157
⫺0.875 ⫾ 0.285

.3559
.0348
.0059
.3349
.0218
.0033

⫺0.317 ⫾ 0.087
1.225 ⫾ 0.143
0.569 ⫾ 0.241
⫺0.185 ⫾ 0.221
0.810 ⫾ 0.159
⫺0.851 ⫾ 0.177

.1526
.0038
.0167
.4149
.1402
.001

.3920
.0416
.2367
.4720
.1009
.2078

a

ADT, Ankle dorsi flexor torque in early stance; APT, ankle plantar flexor torque in late stance; HET, hip extensor torque in early stance; HFT, hip flexor torque
in late stance; KET, knee extensor torque in early stance; KFT, knee flexor torque in late stance; PAD-P, pain condition; PAD-PF, pain-free condition.
a
Differences between PAD-PF and control (P ⬍ .05 is significant).
b
Differences between PAD-P and control (P ⬍ .05 is significant).
c
Differences between PAD-PF and PAD-P (P ⬍ .05 is significant).

Table IV. Group means and standard deviations (in W/kg) for joint powers of the ankle, knee, and hip joint for
peripheral arterial disease (PAD) and control groups

Variable
A1
A2
A3
K1
K2
K3
H1
H2
H3

PAD (N ⫽ 20)

Control
(N ⫽ 16)

PAD-PF

P

PAD-P

Pb

Pc

⫺0.650 ⫾ 0.295
⫺0.550 ⫾ 0.143
2.957 ⫾ 0.686
⫺0.986 ⫾ 0.387
0.527 ⫾ 0.305
⫺0.882 ⫾ 0.324
0.604 ⫾ 0.252
⫺0.937 ⫾ 0.263
0.706 ⫾ 0.237

⫺0.412 ⫾ 0.210
⫺0.558 ⫾ 0.171
2.437 ⫾ 0.445
⫺0.645 ⫾ 0.369
0.293 ⫾ 0.213
⫺0.622 ⫾ 0.206
0.458 ⫾ 0.161
⫺0.665 ⫾ 0.207
0.603 ⫾ 0.182

.061
.4584
.0045
.0066
.0059
.0028
.0316
.0003
.1065

⫺0.375 ⫾ 0.192
⫺0.549 ⫾ 0.308
2.178 ⫾ 0.510
⫺0.731 ⫾ 0.452
0.337 ⫾ 0.244
⫺0.580 ⫾ 0.249
0.478 ⫾ 0.165
⫺0.699 ⫾ 0.205
0.569 ⫾ 0.175

.0171
.4378
.0001
.0647
.0321
.0015
.023
.001
.0332

.321
.648
.022
.273
.145
.376
.493
.338
.128

a

A1, Ankle power absorption in early stance; A2, ankle power absorption in mid stance; A3, ankle power generation in late stance; H1, hip power generation
in early stance; H2, hip power absorption in mid stance; H3, hip power generation in late stance; K1, knee power absorption in early stance; K2, knee power
generation in early mid stance; K3, knee power absorption in late stance; PAD-P, pain conditions; PAD-PF, pain-free condition.
a
Differences between PAD-PF and control (P ⬍ .05 is significant).
b
Differences between PAD-P and control (P ⬍ .05 is significant).
c
Differences between PAD-PF and PAD-P (P ⬍ .05 is significant).

ported by our joint torque findings, which showed significantly decreased torque development by the hip (HET)
and knee (KET) extensors.12 The demonstrated weakness
of the hip and knee extensors in early stance results in

diminished ability for weight acceptance and control of
forward momentum when a claudicating patient walks. The
demonstrated weakness of the ankle dorsi flexors in early
stance is in agreement with findings our group has previ-
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ously published showing that PAD patients have a “foot
drop” upon heel strike.11
Decreased weight support during the mid-stance
phase. In the early part of the mid-stance phase, the knee
extensors concentrically contract to extend the knee joint,
and in the late part, the hip flexors contract eccentrically to
control the movement of the pelvis during single-leg support. To maintain the energy required for walking,16,17 it is
necessary to straighten the leg and stabilize the pelvis to
maximize the ability to generate potential energy at the
highest point of the body’s center of mass during the gait
cycle. Our work shows that both muscle groups (knee
extensors [K2] and hip flexors [H2]) involved in singlelimb support produce less power in PAD patients than in
controls.
Decreased forward propulsion. In late stance, the
body is propelled forward mainly by the action of the ankle
plantar flexors. Functionally, these muscles contract concentrically and accelerate the leg and the trunk forward to
initiate swing, while decelerating the downward motion of
the trunk (ie, providing forward progression and support).18 Our results in the PAD patients demonstrate that
power generation by way of concentric contractions of the
ankle plantar flexor muscles in late stance (A3) is decreased
in the pain-free condition and worsens in the pain condition. This hypothesis is supported by previous findings
from our and other laboratories demonstrating that PAD
patients have significantly decreased ankle plantar flexor
torques7,12 and strength.13 Our additional findings of decreased knee and hip flexor powers further demonstrate the
failure of the PAD limb to appropriately use these muscle
groups to assist the ankle plantar flexors to accelerate the
trunk forward.
Potential clinical implications for the observed gait
abnormalities. Our findings for the temporal and spatial
gait parameters provide definitive evidence of abnormal
temporal and spatial parameters in patients with PAD and
confirm the generally accepted thought that claudicating
patients have an abnormal gait5 that leads to increased
energy cost and earlier fatigue.19 More importantly, our
advanced analysis with joint torques and powers provides a
more detailed delineation of the gait disturbance than that
previously documented by our group and others using
spatial (joint angles)11,12,20,21 and temporal (velocity, cadence, and step/stride characteristics) parameters.5,6,20
When the abnormalities of joint torques and powers in
PAD are compared with other conditions, our values are in
line with those of healthy elderly patients and elderly patients with osteoarthritis.22-25 In contrast, however, the
gait biomechanics of PAD patients appear to be significantly worse than healthy elderly individuals and those with
severe arthritis. Specifically, our data demonstrate that from
the first few steps they take and before they experience any
muscle pain, claudicating patients walk with a 26% decrease
(vs controls) of their ankle plantar flexor power compared
with a 13% for elderly osteoarthritis patients.26 Arthritis
patients compensate for the 13% decrease in the power of
their ankle plantar flexors by increasing the power of their
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knee and hip extensors by 13% and 28%, respectively.23 In
marked contrast to the arthritic patients, claudicating patients demonstrate a drop of compensatory power in these
muscle groups by 39% and 14%, respectively.23 From a
biomechanical standpoint, claudication produces a considerably worse functional limitation than osteoarthritis. Our
data support the findings that claudicating patients typically
gather around the extreme low end of the physical activity
spectrum27 and experience a severe decline in all domains
of physical function.6,28
Potential mechanisms for the observed gait
abnormalities. The present data demonstrate significant
abnormalities in the gait of claudicating patients that are
present at the initiation of ambulation and before the onset
of pain. Work of other investigators evaluating PAD patients has shown that tissue oxygen levels and blood flow in
the leg during the first few steps of walking, are very similar
to (and sometimes even higher than) those of controls.29-31
These results together with our finding of gait impairments
present within the first few steps taken by the patient
suggest that a mechanism other than blood flow is responsible for a significant portion of the limb dysfunction of
claudication. This conclusion is supported by the work of
McDermott et al,32 who measured muscle strength in PAD
patients using a 5-second maximal isometric strength assessment. This test, which is independent of blood flow,
demonstrated that muscle strength in PAD patients is
significantly reduced compared with controls, again indicating that blood flow is not the only determinant of the
dysfunction of claudicating muscle.
These baseline biomechanical impairments likely reflect
a muscle metabolic myopathy and an axonal polyneuropathy in the lower extremities of patients with PAD.33-35
Specifically, a number of reports have documented a metabolic myopathy in the PAD muscle that is related to
defective mitochondrial bioenergetics, oxidative damage,
and inflammation in the skeletal muscle34,36-39 Furthermore, there is accumulating evidence suggesting that
chronic ischemia in patients with PAD results in a consistent pattern of electrodiagnostic abnormalities indicating
axonal nerve loss.35,37
Our data further demonstrate that certain baseline impairments worsen after the onset of claudication pain. This
reflects exercise-induced ischemia and increased workload,
restricting lower extremity bioenergetics and producing
muscle pain. Because of this ischemia-induced neuromyopathy, patients with claudication become severely debilitated and adopt a sedentary lifestyle characterized by limited use of the myopathic limb, which may exacerbate the
neuromyopathy. Fig 2 illustrates a proposed pathway linking these basic pathophysiologic mechanisms (exerciseassociated ischemia-reperfusion, myopathy, neuropathy)
with the specific biomechanic deficits identified in this
work. The involvement by each one of these mechanisms
and the way they are related to the clinical biomechanical
findings of leg dysfunction should be the focus of intense
future investigation and may hold the key to understanding
PAD pathophysiology.
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affecting the proximal arterial tree, the muscle groups most
affected by the chronic ischemia are the hip flexors and
extensors, the knee extensors, and the ankle plantar flexors.
These findings introduce new insights into the pathophysiology of the claudicating gait. In the future, these advanced biomechanical techniques will provide for detailed
objective and quantitative evaluation of the gait deficit of
the claudicating patient, allowing for evaluation of new
treatment and rehabilitation strategies.
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